HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alliance Pharmaceutical's Imavist

This article was originally published in The Gray Sheet

Executive Summary

Ultrasound contrast agent FDA "approvable" letter completes review of the firm's new drug application, the firm announces Aug. 21. The NDA incorporated data from two Phase III multi-center studies on endocardial border delineation in about 500 U.S. patients and was submitted in October 1999. The product was developed jointly by Alliance and The German firm Schering AG. Alliance says it will "work closely with FDA to satisfy the remaining requirements" before final approval of the drug, which will be marketed by Schering
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel